Evidence map›Paper›PMID 41619795›Full record

Trial reportJNCI cancer spectrum2026

Feasibility evaluation of a virtual lifestyle intervention for early-stage breast cancer survivors undergoing chemotherapy.

Sim Yee Cindy Tan, Isaac Yeboah Addo, Gemma Collett, Emily Price, Eliza R Macdonald, Shannon Gerber, Jane Turner, Liane Lee, Hau Yi Yau, Jaclyn Spencer and 11 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Sim Yee Cindy TanConcord Cancer Centre, Concord Repatriation General Hospital, NSW, Australia.ORCID 0000-0002-8188-9395
Isaac Yeboah AddoFaculty of Health and Medicine, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0001-8603-8306
Gemma CollettFaculty of Health and Medicine, University of Sydney, Sydney, NSW, Australia.
Emily PricePsycho-Oncology Co-operative Research Group, School of Psychology, University of Sydney, Sydney, NSW, Australia.
Eliza R MacdonaldConcord Cancer Centre, Concord Repatriation General Hospital, NSW, Australia.ORCID 0000-0001-5372-8378
Shannon GerberConcord Cancer Centre, Concord Repatriation General Hospital, NSW, Australia.
Jane TurnerConcord Cancer Centre, Concord Repatriation General Hospital, NSW, Australia.
Liane LeeFaculty of Health and Medicine, University of Sydney, Sydney, NSW, Australia.ORCID 0009-0008-2251-2230
Hau Yi YauFaculty of Health and Medicine, University of Sydney, Sydney, NSW, Australia.
Jaclyn SpencerNutrition and Dietetics Department, Concord Hospital, Concord, NSW, Australia.ORCID 0000-0002-9400-6993
Sama SaleemNutrition and Dietetics Department, Concord Hospital, Concord, NSW, Australia.
Antonia PearsonNorthern Beaches Hospital, Frenchs Forest, Sydney, NSW, Australia.ORCID 0000-0001-6966-5586
Frances BoylePatricia Ritchie Centre for Cancer Care and Research, Mater Hospital, Sydney, NSW, Australia.
Stephen Della-FiorentinaSouthern Highlands Cancer Centre, Bowral, NSW, Australia.ORCID 0000-0003-1017-5595
Belinda E KielyConcord Cancer Centre, Concord Repatriation General Hospital, NSW, Australia.ORCID 0000-0002-1662-3523
Natalie TaylorImplementation to Impact, School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia.ORCID 0000-0002-0280-0883
Jasmine YeeFaculty of Health and Medicine, University of Sydney, Sydney, NSW, Australia.
Richard De Abreu LourencoCentre for Health Economics Research and Evaluation, University of Technology, Sydney, NSW, Australia.ORCID 0000-0002-5978-8774
Adrian BaumanSchool of Public Health, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0002-0369-4621
Haryana M DhillonPsycho-Oncology Co-operative Research Group, School of Psychology, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0003-4039-5169
Janette L VardyConcord Cancer Centre, Concord Repatriation General Hospital, NSW, Australia.ORCID 0000-0002-5739-5790

Funding

National Breast Cancer FoundationNational Health Medical Research Council APP1176221Professor Martin Tattersall Early Career Researcher Award SchemeUniversity of Sydney
6 · The paper itself

Abstract

backgroundWeight gain and physical inactivity during chemotherapy for patients with early-stage breast cancer are common. We sought to investigate the feasibility of a virtual lifestyle (exercise and diet) intervention for breast cancer survivors during chemotherapy.

methodsThis single-arm phase 2 trial delivered 12 weekly 1-hour telehealth sessions of supervised exercise and diet education to breast cancer survivors (patients with stage I-III disease) starting neoadjuvant chemotherapy. Screening, recruitment, intervention, and study assessments completed at baseline (T0), immediately after the intervention (T1), and 3 months after the intervention (T2) were conducted by telehealth in 2022-2023. The primary outcome was that at least 60% of participants achieved 50% of the predetermined exercise and dietary goals. Secondary outcomes were acceptability (participation, attendance, completion), physical health, and lifestyle outcomes.

resultsOf 73 referrals, 60 individuals were eligible, 58 (97%) provided consent, 51 (85%) commenced the intervention, and 34 (57%) completed at least 1 postintervention assessment (completion rate = 67%). The mean (SD) age of participants was 51 (8.8) years, and 50% of participants were receiving neoadjuvant chemotherapy. Attendance was lower for exercise than for diet sessions (44% vs 62% attended ≥75% sessions). At T1, 36% of participants adhered to at at least 50% of the preset goals, improving at T2 (62.5%). Weight was not statistically significantly different between T0 and T1 (P = .199) but increased substantially at T2 (P = .018). Average waist circumference was reduced at T1 (‒1.9 cm, P = .014) and at T2 (‒3.3 cm, P < .001). Weekly exercise time increased by 38.5 minutes from T0 to T1 (P = .038), and the proportion of participants who met exercise guidelines improved from 6% (T0) to 41% (T2).

conclusionOur primary outcome was not achieved immediately after the intervention but was observed 3 months later. Individuals completing the intervention attended at least half the diet and exercise sessions during chemotherapy. Results of this study will inform design of a phase 3 study.

Indexed as

Breast NeoplasmsCancer SurvivorsExercise TherapyLife StyleAdultExerciseFeasibility StudiesFemaleHumansMiddle AgedNeoadjuvant TherapyNeoplasm StagingPatient ComplianceTelemedicineWeight Gain

Identifiers

PMID41619795
PMCPMC12909259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.